PRECLINICAL
REVIEW MEMO
Composite
Cultured Skin (CCS) was first used in Australia on RDEB (Recessive Dystrophic Epidemolysis Bullosa) patients.
Ortec
International Inc. introduced this product in the USA for the first time in
their clinical studies with burn
patients via G920046. Later the product
was approved for several additional clinical studies: G960200 (indicated for
the treatment of Epidermolysis Bullosa patients), G980037 (indicated for the
treatment venous ulcer patients), G990063 (indicated for the treatment of donor
sites in burn patients), G990204 (indicated for diabetic foot ulcers).
Recently, the same device (OrcelTM Composite Cultured Skin has been
approved for marketing under a humanitarian device exemption (HDE) for EB
patients (H990013).
In
addition to the clinical studies referenced above, the subject device, CCS was
also approved for use in clinical studies for the indication of donor sites in
burn patients. For details regarding the pilot study protocol, see G920046/S28,
G920046/S29, G920046/30.
The
pivotal study was conducted under the IDE, G990063.
The
firm (Ortec International, Inc.) submitted this PMA seeking approval of the
subject device for the indication of donor sites in burn patients. This PMA is
being reviewed only for the safety and efficacy of CCS for the following
indication: For the management of split thickness donor sites in burn patients.
The data submitted in this PMA from other studies (burn study, venous ulcer
study, EB study, and diabetic foot ulcer study) provide additional data
supporting the safety of the product.
The
device under consideration is Composite Cultured Skin (CCS) indicated for the
management of split thickness donor sites in burn patients.
CCS
consists of a collagen matrix in which allogeneic human skin (neonatal male
foreskin) cells (i.e., epidermal keratinocytes and dermal fibroblasts) are
cultured in two distinct layers.
The
collagen cross-linked sponge consists primarily of Type I bovine collagen
laminated on one side with a thin gel layer of acid soluble bovine collagen.
The collagen sponge is a component of the device and such is not a stand-alone
product and is not FDA-approved.
The
fibroblast cells and keratinocyte cells are tested for human and animal
viruses, retroviruses, bacteria, fungi, yeast, mycoplasma, karyology,
isoenzymes and tumorigenicity. The final product is tested for morphology, cell
density and viability, sterility, mycoplasma, and physical container integrity.
The animal-derived reagents used in the manufacture of the device are tested
and found to be negative for viruses, retroviruses, bacteria, fungi, yeast, and
mycoplasma. The bovine material used in the device is obtained from countries
free of BSE.
The
device measures approximately 6 cm x 6 cm. A non-adherent mesh (N-Terface) is
placed on both aspects of the device to protect the cells. The device is
packaged in a plastic tray with protein-free medium containing DMEM.
The
human fibroblast cells and epidermal keratinocyte cells are obtained from
neonatal foreskin. The donors mothers blood is tested and found to be
negative for the following infectious agents: HIV I, HIV II, HTLV I/II, CMV,
HBVsag, HBVab, Herpes 1 and 2, ALT and RPR.
The
cell lines are tested (separately) for the following:
Growth
and morphology evaluation, cytogenetic testing, isoenzyme analysis, in-vivo
tumorigenicity.
The
cell lines (pooled) were tested for the following:
Sterility,
mycoplasma, EBV (Epstein Barr Virus), HSV (Herpes Simplex Virus), HBV, HIV I,
HIV II, HTLV I/II and HHV-VI.
All
the test results meet the acceptance criteria established for the product.
The
following table gives the final release criteria of the device:
Table
1
In-Process
and Final Release Tests are:
|
Test |
Method |
1 |
Appearance
(excess growth/proliferation) |
100%
Visual inspection |
2 |
Dimensions |
Linear
Measurement |
3 |
Viable
Cell Density |
Ortec
TM 07-0004 |
4 |
Cell
viability |
Ortec
TM 07-0004 |
5 |
NHF
Morphology (in-process) |
Ortec
WI 09-0062 |
6 |
NHK
Morphology in-process |
Ortec
WI 09-0062 |
7 |
Endotoxin |
Kinetic
Chromogenic LAL |
8 |
Sterility,
in-process |
USP
Sterility |
9 |
Sterility
Final product |
USP
Sterility |
Shelf Life of CCS Device:
The
sponsor submitted data supporting the shelf life of CCS (see G990063). The data
demonstrated that the subject device, CCS is stable for at least 72 hours
inside a temperature-maintained shipping container.
Mycoplasma Testing:
Each
lot manufactured is tested for mycoplasma.
Cell Lines:
In
HDE H990013, the sponsor provided data in support of two cell lines that will
be used in product manufacture. They are FS-143
and FS-145.
In
this PMA (P010016), the sponsor provides data for cell strain FS-148.
Donor
Mothers Blood Test results were also provided.
The
following table gives presents type of tests performed on FS-148 NHK/NHF
strain.
Note:
NHK stands for normal human keratinocytes; NHF stands for normal human
fibroblasts.
Table
2
Cell
Testing on FS 148 NHK/NHF Cells
Test |
FS-148 NHK/ NHF |
Keratinocytes & Fibroblasts (not pooled) |
|
Growth & morphology
evaluation |
|
Cytogenetic Testing
(Karyotype analysis) |
Pass
(NHF) |
Isoenyzme analysis |
Pass
(NHF) |
In-vitro tumorigenicity
(soft agar) |
Not
tumorigenic |
In-vivo tumorigenicity
(nude mice) |
Not
tumorigenic |
Keratinocytes & Fibroblasts pooled |
|
Sterility |
Sterile |
Mycoplasma cultivable
& non-cultivable |
Negative |
In vitro virus - MRC-5,
Vero & MDBK |
Pass |
EBV PCR |
Negative |
HHV-6- PCR |
Negative |
HBV PCR |
Negative |
HIV-I PCR |
Negative
|
HIV II PCR |
Negative |
HTLV- I/II |
Negative |
HIV-1 co-cultivation &
antigen capture |
Negative |
Table 3
The cytokine profiles
Cytokine |
CCS Production |
bFGF |
+ |
EGF |
+ |
GM-CSF |
+ |
IL-1a |
+ |
IL1b |
+ |
IL-6 |
+ |
IFN-g |
- |
KGF-1 |
+ |
M-CSF |
+ |
PDGF |
+ |
TGF-a |
+ |
TGF-b1 |
+ |
TGF-b2 |
+ |
TNF-a |
+ |
VEGF |
+ |
+ Present
- Undetectable
The
sponsor has developed a cryo-preserved version of the product called Cryo-CCS.
It should be noted that the fresh form of CCS is the only product that was used
in the treatment of donor sites patients.
Literature
data Vogt, et al Platic and Reconstructive Surgery, 102, 117 (1998) on cytokine
concentrations in human wound fluids are available. The following are the data
obtained from 16 patients:
IGF-1 (21-41 ng/ml)
EGF (3-63 pg/ml)
b-FGF (3- 60 pg/ml)
PDGF AB (40- 200 pg/ml)
IL-1a (10-200 pg/ml)
TGF-b (60 - pg/ml)
TGF-b2 (10 30 pg/ml)
IGF-1 binding protein 1 (1-10 ng/ml)
IGF-1 binding protein 3 (1 - 300 ng/ml)
The growth factors IL-1a, TGF-b2, b-FGF and EGF
are present in higher concentrations in the subject device than in the
patients wound fluid (literature values).
Biocompatibility of Collagen
Sponge:
The
following biocompatibility studies were conducted on the collagen sponge:
Cytotoxicity,
hemolysis, sensitization, acute systemic toxicity, subchronic toxicity,
mutagenicity, rabbit pyrogen test. All tests were negative.